Management of 2-4 cm Papillary Thyroid Carcinoma: Risk of Recurrence Compared to 1-2 cm and >4 cm
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim Min Hoi | - |
dc.contributor.author | Lee Joon-Hyop | - |
dc.contributor.author | Kim Yun Yeong | - |
dc.contributor.author | Chun Yong Soon | - |
dc.contributor.author | Park Heung Kyu | - |
dc.contributor.author | Choi Sang Tae | - |
dc.contributor.author | Kang Jin Mo | - |
dc.contributor.author | Chung Yoo Seung | - |
dc.date.available | 2020-12-27T05:40:07Z | - |
dc.date.created | 2020-12-27 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 2508-8149 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79402 | - |
dc.description.abstract | Purpose Clinicians still debate how to manage 2–4 cm papillary thyroid carcinoma (PTC). To understand the characteristics and prognosis of these tumors, we compared clinicopathological prognostic factors and prognosis among 1–2 cm, 2–4 cm, and >4 cm PTC. Methods We retrospectively reviewed the medical records of 2,079 patients with primary PTC >1 cm who were diagnosed between 2002 and 2017. Results The patients' mean age was 47.9±12.5 years, and 83.2% were women. The follow-up period was 81.1±41.8 months. The tumor recurred in 138 patients (6.6%), and thyroid cancer-related death developed in 3 cases (0.1%). As tumor size increased, so did the proportion of male patients, lymphovascular invasion, resection margin positivity, lymph node (LN) metastasis, metastasis in >5 LNs, T4, N stage, and M stage. Recurrence increased linearly according to tumor size, as did distant metastasis as first recurrence and progression to distant metastasis. Tumor size, N stage, metastasis in >5 LNs, and LN metastasis were significant independent risk factors for PTC recurrence. The recurrence rate of 2–4 cm PTC was 13.4%, while the risk of recurrence was 3 times higher than in 1–2 cm PTC. The 5-year recurrence free survival (RFS) rates of 1–2 cm, 2–4 cm, and >4 cm PTC were 97.0%, 88.0%, and 74.0%, respectively, while the 10-year RFS rates were 95.0%, 84.0%, and 71.0%. Conclusion The 2–4 cm PTC may be pathologically distinct from 1–2 cm PTC and should be treated differently. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한갑상선-내분비외과학회 | - |
dc.relation.isPartOf | The Journal of Endocrine Surgery | - |
dc.title | Management of 2-4 cm Papillary Thyroid Carcinoma: Risk of Recurrence Compared to 1-2 cm and >4 cm | - |
dc.title.alternative | Management of 2-4 cm Papillary Thyroid Carcinoma: Risk of Recurrence Compared to 1-2 cm and >4 cm | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.16956/jes.2020.20.4.78 | - |
dc.identifier.bibliographicCitation | The Journal of Endocrine Surgery, v.20, no.4, pp.78 - 87 | - |
dc.identifier.kciid | ART002658889 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 87 | - |
dc.citation.startPage | 78 | - |
dc.citation.title | The Journal of Endocrine Surgery | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kim Min Hoi | - |
dc.contributor.affiliatedAuthor | Lee Joon-Hyop | - |
dc.contributor.affiliatedAuthor | Kim Yun Yeong | - |
dc.contributor.affiliatedAuthor | Chun Yong Soon | - |
dc.contributor.affiliatedAuthor | Park Heung Kyu | - |
dc.contributor.affiliatedAuthor | Choi Sang Tae | - |
dc.contributor.affiliatedAuthor | Kang Jin Mo | - |
dc.contributor.affiliatedAuthor | Chung Yoo Seung | - |
dc.subject.keywordAuthor | Papillary thyroid carcinoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Disease free survival | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.